Since intestinal dysbiosis often causes a systemic inflammation that can lead to disturbs in different body districts, SynBalance strains have been tested for other disorders related to gut microbiome imbalance. For example, disturbances in the balance of the skin microbiota are often linked to dysfunctions in the communication between the gut microbiota and the brain. This is known as the gut-brain axis. In this context, in vitro investigations on the stimulation of serotonin, GABA and LSD1 production have been carried out. From this screening in vivo studies related to sleeping/mood disorders and changes in cognitive functions of students under stress have been carried out. Furthermore, an additional clinical trial has been conducted on acne disease, to confirm the interaction of SynBalance® with the gut-skin axis, beyond AD application.
Finally, since conditions related to IBS can include in addition to the classic abdominal symptoms, also diseases of the urogenital tract, in vitro tests were performed on the possible urogenital implications of IBS, evaluating the antimicrobial activity of the strains on pathogens related to prostatitis.
All these screenings have been used for the development of new application of SynBalance® probiotics, with the creation of new synergies among strains.